Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Insulin pen Stories

2013-09-16 12:27:44

MONTREAL, Sept. 16, 2013 /PRNewswire-iReach/ -- Major marketing and distribution firm montméd will make DiaClin skin care products, designed for general and diabetes use, available for Canadian consumers (Photo: http://photos.prnewswire.com/prnh/20130916/MN80061) International medical supply distributor and manufacturing firm montméd Inc. today announced that it will soon launch the DiaClin line of general and diabetes skin care products in the Canadian consumer marketplace. DiaClin offers...

2013-08-21 12:27:19

First insulin injection device to combine half-unit dosing with a memory function to help patients better manage their diabetes PLAINSBORO, N.J., Aug. 21, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the insulin device NovoPen Echo(®). This marks the first and only pen device in the U.S. with half-unit dosing and a memory function that records the dose and time passed...

2013-08-06 08:21:25

Charlie Kimball Makes History as First Driver with Diabetes to Win an IndyCar Race PLAINSBORO, N.J., Aug. 6, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, is pleased to announce that Charlie Kimball, driver of the No. 83 NovoLog(®) FlexPen(®) Honda, has become the first and only licensed driver with diabetes to win an IndyCar race. This milestone was achieved as the Novo Nordisk Chip Ganassi Racing Team saw its first-ever IndyCar Series victory, secured at the...

2013-06-21 08:25:10

Addition of EasyFlow(TM) Technology to BD Ultra-Fine(TM) Nano(TM) 4mm Pen Needles Increases Confidence and Convenience of Injections FRANKLIN LAKES, N.J., June 21, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. launch of the BD Ultra-Fine(TM) Nano(TM) 4mm Pen Needle with EasyFlow(TM) Technology. EasyFlow Technology makes it easier and faster for people with diabetes to...

2013-04-05 08:23:44

Enter today for a chance to win a trip to the 2013 IndyCar® Series finale BIRMINGHAM, Ala., April 5, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and IZOD IndyCar Series driver Charlie Kimball today kicked off a new contest asking people to support Charlie by encouraging their friends and family to join the Race with Insulin(®) crew. Now through September 15, by sharing Kimball's story about the importance of team support with two or more friends or...

2013-01-22 08:30:40

PRINCETON, N.J., Jan. 22, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog(®) Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog(®) (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they're giving back to their local communities. To view the multimedia assets associated with this release, please click:...

2012-06-11 10:24:37

PARIS, France, June 11, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States, providing further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus® (insulin glargine [rDNA origin]...

2012-05-22 02:28:04

PRINCETON, N.J., May 22, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. With the expansion of its pediatric indication, Levemir(®) is now available for type 1 diabetes patients from age two through adulthood and adult patients with type 2 diabetes. To view the multimedia...

2012-04-09 06:24:24

PRINCETON, N.J., April 9, 2012 /PRNewswire/ -- Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza(®) (liraglutide [rDNA origin] injection) to include data showing superior blood sugar control when compared to Januvia(®) (sitagliptin). Victoza(®) also provided greater weight reduction. Both products were taken in combination with metformin in adults with type 2 diabetes. To view the multimedia assets associated...

2012-04-02 02:28:55

PRINCETON, N.J., April 2, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for a pregnancy Category B classification, indicating that Levemir(®), when used in pregnant women with diabetes, did not increase the risk of harm to the unborn baby. To view the multimedia assets associated with this release, please click:...